Serum Squamous Cell Carcinoma Antigen Level in Cirrhotic Chronic Hepatitis C Patients With and Without Hepatocellular Carcinoma
Abstract
This study will be carried out on 500 personnel divided into five groups : Group A: 100 cases of hepatocellular carcinoma without interventions. Group B: same 100 cases of group A before and 3 months after successful interventions.Group C: 100 cases of established cirrhosis. Group D: 100 cases with chronic hepatitis C virus infection without established cirrhosis. Group E: 100 healthy individuals as controls.
Methods: Sera from selected patients and controls have been used for estimation of SCC-Ag using CanAg SCC EIA.
Results: high significant increase in serum SCCA level in patients with HCC (groupA and groupB) when compared to cirrhotic, chronic HCV and control groups (P < 0.001). Positive significant correlation was found between AFP and serum SCCA level .The best cut-off value to differentiate HCC patients from cirrhotic patients was 3.2 ng/ml for SCCA yielded with 80% sensitivity and 90% specificity. When combined sensitivity of both markers was calculated in our study at the best-chosen cutoff values (SCCA 3.2 ng/ml and AFP 200 ng/ml) sensitivity improved to 93%.
Conclusion: Combined SCCA and AFP can be used as in diagnosis of HCC and follow up 3 months after therapeutic intervention.
Keywords
Full Text:
PDFReferences
[1] Lok, A., Seeff, L., & Morgan, T. (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C related advanced liver disease. Gastroenterology, 136, 138-48.
[2] El-Zayadi, A., & Badran, H. (2005). Hepatocellular carcinoma in Egypt: A single center study over a decade. World J Gastroenterol, 11, 5193–8.
[3] Peng, S.Y., Chen, W., & Lai, P., et al. (2004). High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age 53 and beta-catenin mutations. Int J Cancer, 112, 44-50.
[4] Giannelli, G., & Antonaci, S. (2011). New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Disease, 38, 854-9.
[5] Biasiolo, A., Chemello, L., & Quarta, S. (2008). Squamous cell carcinoma antigen (SCCA) detection in patients with HCV infection and rheumatoid factor seropositivity. J Viral Hepat, 15, 246-9.
[6] Issa, H., Awadallah, A., & Soliman, M. (2011). Evaluation of serum chromogranin A as a useful tumor marker for diagnosis of hepatocellular carcinoma. Journal of American Science, 7, 999-1007.
[7] Feng, W., Wang Z. B., & Meng, W. C., et al. (2004). Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Surgical Onco, 11, 1061-69.
[8] Molinari, M., Kachuray, J., Dixonz, ., Suehiro, Y., Morioka, H., & Fordtran, B., et al. (2006). Transarterial chemoembolisation for advanced hepatocellular carcinoma: Results from a North American Cancer Centre. Clinical Oncology, 18, 684-92.
[9] Hussein, M., Ibrahim, A., & Abdella, H. (2008). Evaluation of serum squamous cell carcinoma antigen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Indian J Cancer, 45, 167-72.
[10] El Ezawy, H., Shebil, N., & Mounis, A. (2012). Assessment of serum SCCA and KL-6 as tumor markers and their correlation with tumor size. Journal of American science, 8, 172-9.
[11] Bin, X., Fang, G. S., Liu, S, H., Kim, T., Takahashi, S. (2008). SCCA level in peripheral blood in patients with hepatocellular carcinoma before and after TACE. J Huazhong Univ Sci Technol 28, 645-8.
[12] Trevisani, F., Daniela, B., & Gianluca, F. (2012). Serum SCCA as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. Open Journal of Gastroenterology, 2, 56-61.
DOI: http://dx.doi.org/10.3968/gh.v1i1.5289
Refbacks
Copyright (c)
Reminder
We are currently accepting submissions via email only.
The registration and online submission functions have been disabled.
Please send your manuscripts to gh@cscanada.net,or gh@cscanada.org for consideration.
We look forward to receiving your work.
Articles published in Gastroenterology and Hepatology are licensed under Creative Commons Attribution 4.0 (CC-BY).
GASTROENTEROLOGY AND HEPATOLOGY Editorial office
Address: 1055 Rue Lucien-L'Allier, Unit #772, Montreal, QC H3G 3C4, Canada.
Telephone: 1-514-558 6138
Website: Http://www.cscanada.net Http://www.cscanada.org
E-mail:gh@cscanada.net, gh@cscanada.org
Copyright © 2010 Canadian Research & Development Centre of Sciences and Cultures